financetom
Business
financetom
/
Business
/
What's Going On With Rivian Stock Wednesday?
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
What's Going On With Rivian Stock Wednesday?
Jul 3, 2024 6:30 AM

Rivian Automotive Inc ( RIVN ) shares are volatile Wednesday following reports the company has no plans to produce vehicles with Volkswagen under their recently announced joint venture.

What Happened: Rivian and Volkswagen do not plan to partner on hardware or produce vehicles together as part of the planned joint venture announced last week, per Reuters.

The news follows reports from German media outlet Handelsblatt earlier in the day that the two companies were in talks to expand their software partnership to hardware and joint production. Sources familiar with the matter reportedly said the two companies were discussing potential production of the R2 platform at Volkswagen's plant in South Carolina, which is being built right now.

“There are no plans for production of vehicles with Volkswagen Group,” a Rivian spokesperson reportedly told Reuters.

Rivian said there are no changes to its R2 production plans. The company still intends to build the R2 platform vehicles at its plant in Normal, Illinois, and will ramp up its Georgia plant from there.

Rivian and Volkswagen announced last Tuesday that the automakers would enter into a joint venture to create next-generation software-defined vehicle platforms to be used in both companies’ future electric vehicles. Volkswagen will initially invest $1 billion and is expected to invest an additional $4 billion over time as part of the transaction.

See Also: EXCLUSIVE: Top 10 Most Searched Tickers On Benzinga Pro In First Half 2024 – Where Do Nvidia, Tesla, Palantir, GameStop Rank?

RIVN Price Action: Rivian shares were down about 1.5% in extended trading Tuesday before bouncing back in early trading Wednesday. The stock was last down 0.11% at $14.87, according to Benzinga Pro.

Photo: courtesy of Rivian.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Factbox-More companies adopt co-CEO structure
Factbox-More companies adopt co-CEO structure
Sep 30, 2025
(Reuters) -Companies are increasingly opting for a co-CEO structure as their operations become expansive, diverse and complicated. Notably, Oracle, Comcast ( CMCSA ) and Spotify ( SPOT ) have recently appointed joint CEOs to oversee their business operations, reflecting the growing trend among high-profile firms to share top leadership roles. Below is a list of companies that have adopted such...
Labcorp to Collaborate With Roche to Advance Digital Pathology Capabilities
Labcorp to Collaborate With Roche to Advance Digital Pathology Capabilities
Sep 30, 2025
07:44 AM EDT, 09/30/2025 (MT Newswires) -- Labcorp ( LH ) said Tuesday it will implement Roche's slide scanners under a new collaboration aimed at advancing digital pathology capabilities. The implementation of the Ventana DP 600 and DP 200 slide scanners will help pathologists in diagnosing patients using digital images and would support future artificial intelligence integration, the company said....
Markets See a Rate Cut This Week at India's Central Bank But Economist Expect A Hold, Says Scotiabank
Markets See a Rate Cut This Week at India's Central Bank But Economist Expect A Hold, Says Scotiabank
Sep 30, 2025
07:42 AM EDT, 09/30/2025 (MT Newswires) -- A hold would surprise markets more than economists when the Reserve Bank of India offers its latest decision on Wednesday, said Scotiabank. Markets are roughly 80% priced for a cut, but the majority of economists lean toward a hold, noted the bank. The RBI has the cover to cut, given that inflation remains...
Ocular Therapeutix Prices $475 Million Underwritten Common Stock Offering
Ocular Therapeutix Prices $475 Million Underwritten Common Stock Offering
Sep 30, 2025
07:44 AM EDT, 09/30/2025 (MT Newswires) -- Ocular Therapeutix ( OCUL ) said Tuesday it has priced the underwritten offering of more than 37.9 million common shares at $12.53 per share, for gross proceeds of $475 million before fees and expenses. The offering is expected to close on or about Oct. 1, subject to customary closing conditions, the biopharmaceutical company...
Copyright 2023-2026 - www.financetom.com All Rights Reserved